Danielle Kovac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Danielle Kovac has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- David M. Salerno
Department of Pharmacy NewYork‐Presbyterian Hospital New York New York USA
4 shared publications - Douglas L. Jennings
Thomas J. Long School of Pharmacy University of the Pacific Sacramento California USA
4 shared publications - Jason Choe
Department of Pharmacy New York Presbyterian Hospital New York City New York USA
4 shared publications - Jessica Hedvat
NewYork‐Presbyterian Hospital Department of Pharmacy New York New York USA
4 shared publications - Nicholas W. Lange
NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA
3 shared publications Tara Shertel
Department of Pharmacy New York Presbyterian Hospital New York New York USA
3 shared publications
Latest Publications
- 8 August 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (8) , e15420
Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation
Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.
- 8 August 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (8) , e15420
Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation
Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.
- 7 February 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (4) , 367-375
Solid organ transplant residency research publication rates and characteristics associated with successful publication
Introduction: Publication rates, characterization, and assessment for predictors of publication in post‐graduate year 2 (PGY2) solid organ transplant (SOT) are lacking.Objectives: This study was conducted to determine the publication rate of PGY2 SOT pharmacy resident projects, understand practices surrounding resident research, and assess characteristics of published manuscripts.Methods: An electronic survey of PGY2 SOT residency programs was distributed. Invitation for participation was sent by email to residency program directors (RPDs), and information related to the PGY2 SOT program, RPDs, research mentors/preceptors, residents, and each research project was gathered for residents graduating between 2016 and 2019. Characteristics influencing publication success were assessed with multivariate logistic regression modeling.Results: Thirty‐eight RPD responses were analyzed (67.8% response rate). All PGY2 SOT programs were American Society of Health‐System Pharmacists (ASHP) accredited, 92% were at academic medical centers, and more than 80% were active over 6 years with a median of 10 (interquartile range [IQR] 5–13) graduated residents. In total, 35/97 (36.1%) of SOT PGY2 research projects were published, 22.7% intend to submit or have a manuscript under revision, and 39.2% will not pursue publication. Of published projects, 81% were in medical journals. Median impact factor was 2.9 (IQR 1.5–2.9). Programs active more than 10 years (odds ratio [OR] 4.0, 95% confidence interval [CI] 1.41–11.17, p = 0.009) and utilization of additional resources (OR 4.2, 95% CI 1.23–14.37, p = 0.022), including availability of a biostatistician/epidemiologist or pharmacy student, were independently predictive of publication. Fifty percent of RPDs rated their programs as either “effective” or “extremely effective” in enabling publication. Perceived barriers to publication, most often continuity of PGY2 SOT involvement after residency, were identified.Conclusion: Overall, 36.1% of PGY2 SOT pharmacy resident research projects achieved publication over a 4‐year period at the time of the survey. Years of PGY2 SOT program activity and having additional resources were independently associated with publication.
- 7 February 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (4) , 367-375
Solid organ transplant residency research publication rates and characteristics associated with successful publication
Introduction: Publication rates, characterization, and assessment for predictors of publication in post‐graduate year 2 (PGY2) solid organ transplant (SOT) are lacking.Objectives: This study was conducted to determine the publication rate of PGY2 SOT pharmacy resident projects, understand practices surrounding resident research, and assess characteristics of published manuscripts.Methods: An electronic survey of PGY2 SOT residency programs was distributed. Invitation for participation was sent by email to residency program directors (RPDs), and information related to the PGY2 SOT program, RPDs, research mentors/preceptors, residents, and each research project was gathered for residents graduating between 2016 and 2019. Characteristics influencing publication success were assessed with multivariate logistic regression modeling.Results: Thirty‐eight RPD responses were analyzed (67.8% response rate). All PGY2 SOT programs were American Society of Health‐System Pharmacists (ASHP) accredited, 92% were at academic medical centers, and more than 80% were active over 6 years with a median of 10 (interquartile range [IQR] 5–13) graduated residents. In total, 35/97 (36.1%) of SOT PGY2 research projects were published, 22.7% intend to submit or have a manuscript under revision, and 39.2% will not pursue publication. Of published projects, 81% were in medical journals. Median impact factor was 2.9 (IQR 1.5–2.9). Programs active more than 10 years (odds ratio [OR] 4.0, 95% confidence interval [CI] 1.41–11.17, p = 0.009) and utilization of additional resources (OR 4.2, 95% CI 1.23–14.37, p = 0.022), including availability of a biostatistician/epidemiologist or pharmacy student, were independently predictive of publication. Fifty percent of RPDs rated their programs as either “effective” or “extremely effective” in enabling publication. Perceived barriers to publication, most often continuity of PGY2 SOT involvement after residency, were identified.Conclusion: Overall, 36.1% of PGY2 SOT pharmacy resident research projects achieved publication over a 4‐year period at the time of the survey. Years of PGY2 SOT program activity and having additional resources were independently associated with publication.
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
Open AccessCOVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 15 January 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (3) , e14594
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients
- 15 January 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (3) , e14594
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients
- Open Access
- 11 January 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (7) , 1925-1926
Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants
- 11 January 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (7) , 1925-1926
Open AccessNirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants